This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

Supernus, Britannia, US WorldMeds face amended US antitrust claims over drug for Parkinson’s disease

( October 26, 2022, 22:31 GMT | Official Statement) -- MLex Summary: Sage Chemical and TruPharma filed amended US antitrust claims accusing Supernus Pharmaceuticals, Britannia Pharmaceuticals, and US WorldMeds Partners of engaging in a conspiracy to restrain generic competition for branded Apokyn, a drug used to treat Parkinson’s disease. According to the complaint, the companies manipulated the Food and Drug Administration’s system to slow the approval of Sage’s generic.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents